EGFR and lung adenocarcinoma: The prominent expression of CCR2 in specific clinicopathologic/molecular subgroups of lung adenocarcinomas harboring oncogenic mutations in EGFR and KRAS, as well as in CRCs with microsatellite instability–high status further support the potential for refined patient selection.